PAREXEL is Acquired by Pamplona Capital Management

Article

Applied Clinical Trials

PAREXEL International Corporation announced that Pamplona Capital Management, LLP has acquired all of its outstanding shares, including Parexel's net debt, for $88.10 per share in cash-valued at approximately $5 billion.

Read the full release here.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.